Emergent BioSolutions has entered an agreement with Novavax to provide molecule-to-market contract development and manufacturing services to produce Novavax’s NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M adjuvant. Novavax recently announced that NanoFlu met all primary objectives in its Phase 3 clinical trial evaluating immunogenicity and safety in adults aged 65 and older.   “Emergent is pleased to expand our collaboration with Novavax...